Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Erasca, Inc (ERAS) Pulls Back from 20+pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'
January 7, 2026 12:11 PM ESTErasca, Inc (NASDAQ: ERAS) Pulls Back from 25pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'.
The analyst comments "ERAS [and Revolution Medicines (RVMD, $81.42, Buy)] is trading strong this morning on readthrough from pan-KRAS inhibitor data from BridgeBio Oncology Therapeutics (BBOT; not... More
Morgan Stanley on BridgeBio Oncology Therapeutics, In (BBOT): 'Strong efficacy and tolerability for BBO-8520'
January 7, 2026 11:30 AM ESTMorgan Stanley analyst Sean Laaman reiterated an Overweight rating and $20.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT).
The analyst comments "BridgeBio Oncology Therapeutics (BBOT) announced updated clinical data and pipeline progress across three differentiated programs targeting RAS and PI3K pathways. We provide a summary of the program updates and our views on their clinical merit. BBO-8520 (KRAS G12C ON/OFF... More
